Botox is a commercial botulinum toxin product used therapeutically and cosmetically to reduce abnormal muscle activity and for selected neurologic indications. It works by blocking acetylcholine release at neuromuscular junctions. Clinical use spans spasticity-related disorders, chronic migraine prophylaxis, hyperhidrosis, and wrinkle reduction.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
AbbVie reported Q4 earnings that beat consensus estimates with $16.62 billion in revenue, while facing competitive setbacks in psoriatic arthritis and Medicare pricing challenges for Botox.
AbbVie filed a lawsuit challenging the federal government's decision to include Botox in Medicare's drug price negotiation program, arguing the drug qualifies as a plasma-derived product excluded under the Inflation Reduction Act.
AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06755099 |
Female Sexual Dysfunction Assessment and Managment of Vaginismus |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT06399718 |
A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants |
COMPLETED | PHASE3 |
| NCT06387394 |
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence |
COMPLETED | PHASE3 |
| NCT06218251 |
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines |
COMPLETED | PHASE4 |
| NCT06174688 |
A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
COMPLETED | PHASE3 |
| NCT06137287 |
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants |
COMPLETED | PHASE3 |
| NCT06068855 |
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants |
COMPLETED | PHASE3 |
| NCT05956509 |
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity |
TERMINATED | PHASE1 |
| NCT05573581 |
Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery |
UNKNOWN | PHASE3 |
| NCT05496335 |
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines |
COMPLETED | PHASE1 |
